Miguel Escobar, MD
Hematology · Houston, TXNPI 1437177912
Payments from drug & device makers
Across 649 payments — averaging $1678.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- HEMA Biologics, LLC$159K
- Sanofi$136K
- Novo Nordisk AS$113K
- Takeda Pharmaceuticals U.S.A., Inc.$112K
- Novo Nordisk$103K
- CSL Behring$92K
- plus $376K from 19 others
Across 24 payments — averaging $4783.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- HEMA Biologics, LLC$109K
- F. Hoffmann-la Roche AG$2K
- Bioverativ Therapeutics Inc.$2K
- Regeneron$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| HEMA Biologics, LLC | 141 | $159,238 |
| Sanofi | 43 | $135,502 |
| Novo Nordisk AS | 54 | $112,732 |
| Takeda Pharmaceuticals U.S.A., Inc. | 71 | $111,612 |
| Novo Nordisk | 51 | $102,720 |
| CSL Behring | 73 | $91,684 |
| Bayer | 43 | $84,499 |
| Novo Nordisk Health Care AG | 16 | $56,044 |
| Biomarin Pharmaceutical Inc. | 43 | $40,409 |
| Genentech USA, Inc. | 27 | $31,305 |
| Sanofi US Services Inc. | 3 | $31,164 |
| Regeneron | 8 | $27,654 |
| Sanofi-aventis U.S. LLC | 7 | $21,992 |
| Bioverativ Therapeutics Inc. | 15 | $21,840 |
| Pfizer | 13 | $16,993 |
| Shire North American Group Inc | 17 | $13,124 |
| Kedrion Biopharma Inc. | 6 | $12,224 |
| Genentech, Inc. | 4 | $7,900 |
| Biocryst Pharmaceuticals, Inc. | 1 | $5,559 |
| F. Hoffmann-la Roche AG | 2 | $2,458 |
| Samsung Bioepis Co., Ltd. | 1 | $2,040 |
| Eagle Pharmaceuticals, Inc. | 1 | $400 |
| Spark Therapeutics, Inc. | 2 | $132 |
| Eisai Inc. | 5 | $110 |
| Grifols USA, LLC | 2 | $40 |
How this compares
$1,089,374 in reported general payments places this provider in the 85th percentile of 97 hematology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in Houston
- Swaminathan IyerHouston$10.1M
- Modupe IdowuHouston$8.7M
- Jing YeHouston$4.4M
- Uday PopatHouston$4.4M
- Sunil PatelHouston$3.5M
- Yesid Alvarado ValeroHouston$3.2M
- Siddhartha GangulyHouston$2.4M
- Alexandra IkeguchiHouston$2M
- Gregory KaufmanHouston$868K
- George ChenHouston$715K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.